Trending...
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Tech gains propel Dow Jones past 47,000 as markets reach record highs amid trade tensions
- Hilton Head Realtor becomes Certified Senior Professional
Placed by a Neurosurgeon at the Time of Resection, GammaTile® Therapy Gives Patients a Head STaRT in the Fight Against Brain Tumors, Delaying Tumor Recurrence
TEMPE, Ariz. - Marylandian -- GT Medical Technologies, Inc. today announced its GammaTile® Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors will be spotlighted at the 2021 CNS Annual Meeting exhibition October 18-20 in Austin, Texas, and at the 15th Tumor Section Satellite Symposium which immediately precedes it October 15-16.
"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."
More on Marylandian
Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.
About GT Medical Technologies, Inc.
More on Marylandian
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.
"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."
More on Marylandian
- The AI CEO Partners with D3 Hockey News to Elevate the Voice of Division III Hockey Nationwide
- Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
- Maryland: testpost
- Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.
- Focus: Neurosurgical Oncology
- October 15-16 | JW Marriott, Austin Texas
- GT Medical Technologies booth 200
- Saturday, October 16, 12:15 PM-1:15 PM: GammaTile® Therapy: Technology and Device Overview
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.
- October 18-20 Exhibits | Austin Convention Center
- GT Medical Technologies booth 1750
About GT Medical Technologies, Inc.
More on Marylandian
- Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
- $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Year-Round Deals for Customers With Square Signs
- Aelix Launches "Flow Before Theory" Series on Structured Wholesale Gas and Power
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.
Source: GT Medical Technologies
0 Comments
Latest on Marylandian
- Thousands of Smiles, Millions of Logo Views: RoarFun Brings Emotions Into Premium Retail Spaces with Formula Simulator for Immersive Brand Activation
- Qvarz LLC Expands Global Reach with High-Precision Quartz Cuvettes and Optical Components
- $300 Million Web3 Initiative and ZIGChain Partnership Power $20 Target in Noble Capital Markets Report for SEGG Media (N A S D A Q: SEGG)
- Enrollment Period for Maryland's 2025 Conservation Buffer Initiative Begins November 1st
- Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
- Heritage at South Brunswick's Townhome Models Coming Soon!
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink
- Genuine Smiles Unveils New User-Friendly Website
- Nusign Global Launch Event Concludes Successfully, Embarking on a New International Chapter
- Lift Solutions Holdings Announces Exclusive Distributorship for Advanced Camera and Sensor Products from Automate Matrix
- Political Division and Safety Concerns Drive Record Number of Americans to Seek "Golden Visas," La Vida Survey Finds
- The Citizens Commission on Human Rights of Florida Celebrates Volunteers and Community Partners at the 9th Annual Humanitarian Awards Banquet
- J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
- Words of Veterans & Veterans Growing America Collaboration
